S.W. Bach Initiates Coverage on Novadel
PORT WASHINGTON, N.Y., Oct. 12 /PRNewswire/ -- S.W. Bach & Company, Inc. said
it initiated coverage on NovaDel Pharma Inc. (AMEX:NVD) with a speculative buy
recommendation and a 12-month price target of $4.50. The price target assumes
significant milestones are met in NovaDel's human study of the Lingual Spray
Version of Pfizer's Xanax(R), a leading anti-anxiety drug and the acceptance by
the FDA of the company's new drug application (NDA) for Nitroglycerin Lingual
Spray.
For additional information:
Peter Cardillo
Chief Market Analyst
212 771-7640 S.W. Bach & Company, Inc. is a member of the NASD, CRD number 43522. DATASOURCE: S.W. Bach & Company, Inc.
CONTACT: Peter Cardillo, Chief Market Analyst for S.W. Bach & Company, Inc., +1-212-771-7640
|